Can you give us a bit of history about Guerbet?
Guerbet is a French company that manufactures the contrast agents used in medical imaging, among other things. Our DNA is linked to diagnostics - we are a diagnostic family of companies.
The UK Subsidiary of Guerbet was established in 1994 and is currently based in Solihull. Guerbet Laboratories Ltd has provided England, Scotland and Wales with solutions in Medical Imaging, including a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging.
We were the company that first introduced a macrocyclic gadolinium-based contrast agent used in MRI examination, called Dotarem, which is currently the most widely used macrocyclic gadolinium-based contrast agents (GBCA) in the world1-2. Every three seconds a patient is injected with Dotarem2. Patient-centric care is key for us.
Can you tell us about EluciremTM?
Elucirem represents a breakthrough in radiology innovation as the next generation of gadolinium-based contrast agents. It is a macrocyclic gadolinium-based contrast agent with half the gadolinium dose and up to 3 times higher relaxivity compared to conventional macrocyclic gadolinium-based contrast agents (GBCA) 3-4.
It can be used for MRI scans in adults and children aged two years and older to detect and visualise lesions with abnormal vascularity in the central nervous system and liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system3.
Elucirem is in line with our philosophy of patient safety. In phase III studies, Elucirem demonstrated a safety profile comparable to the active comparator (gadobutrol) in clinical trials 7. The most frequent adverse reactions were injection site pain, headache, nausea, injection site coldness, fatigue and diarrhoea3. Following the Royal College of Radiologists (RCR) and the European Medicines Agency (EMA) recommendations, the dose of GBCA should be minimized 5-6, Elucirem is a lower gadolinium dose solution for patients and radiologist communities.
Can you tell us about EluciremTM?
Elucirem represents a breakthrough in radiology innovation as the next generation of gadolinium-based contrast agents. It is a macrocyclic gadolinium-based contrast agent with half the gadolinium dose and up to 3 times higher relaxivity compared to conventional macrocyclic gadolinium-based contrast agents (GBCA) 3-4.
It can be used for MRI scans in adults and children aged two years and older to detect and visualise lesions with abnormal vascularity in the central nervous system and liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system3.
Elucirem is in line with our philosophy of patient safety. In phase III studies, Elucirem demonstrated a safety profile comparable to the active comparator (gadobutrol) in clinical trials 7. The most frequent adverse reactions were injection site pain, headache, nausea, injection site coldness, fatigue and diarrhoea3. Following the Royal College of Radiologists (RCR) and the European Medicines Agency (EMA) recommendations, the dose of GBCA should be minimized 5-6, Elucirem is a lower gadolinium dose solution for patients and radiologist communities.
The Guerbet team at UKIO 2024, held in Liverpool
The Guerbet team at UKIO 2024, held in Liverpool
How does EluciremTM contribute to environmental sustainability?
It starts of course with production. For us sustainability is key in how we produce our products and deliver them to hospitals.
But also, in using less gadolinium, using half the amount compared to other conventional macrocyclic gadolinium-based contrast agent (GBCA)3, means in effect we’re halving the impact on the environment, which is huge.
How does EluciremTM contribute to environmental sustainability?
It starts of course with production. For us sustainability is key in how we produce our products and deliver them to hospitals.
But also, in using less gadolinium, using half the amount compared to other conventional macrocyclic gadolinium-based contrast agent (GBCA)3, means in effect we’re halving the impact on the environment, which is huge.
How does Guerbet support the wider radiology community?
The key to our relationships is listening - listening and understanding the needs. This lets us then provide the support and knowledge we have to provide better patient solutions, to provide the best possible care and service to both hospitals and patients.
We have a broad portfolio. It’s not just contrast agents we do, we have injectors, we have consumables, servicing, customer servicing.
Really the total portfolio is unique. Each hospital, each patient has a different need and for us that is key.
We also offer local support. We have a dedicated local team who know the company very well and feel a responsibility to provide the best support.
How does Guerbet prioritise building lasting relationships?
We actively seek collaboration and prioritize innovation. Our team, both in the field and in the office, maintains regular contact with our partners. These relationships are key, as our people make the difference.
Field teams meet with partners, understand their needs, and receive support from our office staff. This continuous interaction ensures strong, supportive relationships with our partners.
References:
- Val M. Runge et al., The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011 Dec;46(12):807-16.
- Data on file, Guerbet internal data (2023, Global).* * Data inclusive of the MRI contrast agent brands that belong to Bracco imaging S.p.A, G.E Healthcare, Guerbet Group, and Bayer Pharma AG, in the following countries: Algeria, Argentina, Australia, Austria, Belgium, Bosnia, Brazil, Bulgaria, Canada, Caribbean, Chile, China, Columbia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom, USA, Venezuela. Data exclude generic brands, except GE (Clariscan™) Bayer (Dotagraf), and local generics in Japan
- Elucirem. Summary of Product Characteristics. 12/12/2023.
- Robic C, Port M, Rousseaux O, et al. Invest Radiol. 2019 Aug;54(8):475-484.
- Guidance on gadolinium-based contrast agent administration to adult patients. The Royal College of Radiologists, 2019.
- PRAC confirms restrictions on the use of linear gadolinium agents. Benefit-risk balance of certain linear gadolinium agents no longer favourable. The European Medicines Agency, 2017.
- Loevner LA, Kolumban B, Hutóczki G, et al. Efficacy and Safety of Gadopiclenol for
Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized
Clinical Trial. Invest Radiol. 2023 May 1;58(5):307-313.
Product PI can be found at Guerbet UK Website.
EluciremTM pi_elucirem-jan2024_final-digital-clean-2.pdf (guerbet.com)
More about Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. Guerbet is a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with over 2,700 employees worldwide, we continuously innovate and devote 10% of our sales revenue to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and its turnover was 753 million euros in 2022. For more information, visit: https://www.guerbet.com/en-gb.
Image credit: Saracin / Creatas Video+ / Getty Images Plus
Read more
Built with Shorthand